داركزبان
مراجع

↑  [1. Eriksson, B., et al. "A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery." Journal of Thrombosis and Haemostasis (2007): 1660-1665]
1 2 3 4 5  [2. Yoshiyuki, I., et al. "Biochemical and pharmalogical profile of darexaban, an oral direct Xa inhibitor." European Journal of Pharmacology (2011): 49-55]
1 2  [3. Toshifumi, S., et al. "Identification of UDP-Glucuronosyltransferases Responsible for the Glucuronidation of Darexaban, an Oral Factor Xa Inhibitor, in Human Liver anD Intestine." The American Society for Pharmacology and Experimental Therapeutics (2011): 278-282]
1 2  [4. Katsung, B., S. Masters and A. Trevor. Basic and Clinical Pharmacology 11th Edition. United States of America: McGraw-Hill, 2009]
↑  [5. Turpie, A., et al. "Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthoplasty. A dose finding study (ONYX-2)." Journal of Thrombosis and Haemostasis (2010): 714-721]
1 2  [6. Steg, PG; Mehta, SR; Jukema, JW; Lip, GY; Gibson, CM; Kovar, F; Kala, P; Garcia-Hernandez, A; Renfurm, RW; Granger, CB; Ruby-1, Investigators (2011). "RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome". European heart journal 32 (20): 2541–54. doi:10.1093/eurheartj/ehr334. PMC 3295208. ببمد: 21878434.]
↑  [7. Hirayama, F., et al. "Discovery of N-[2-Hydroxy-6-(4-methoxybenamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor." Journal of Medicinal Chemistry (2011): 8051-8065]
↑  [8. Zhong, Y., et al. "Atrial Fibrillation as a Risk Factor for Stroke: A Retrospective Cohort Study of Hospitalized Medicare Beneficiaries." American Journal of Public Health (1998): 395-400]
↑  [9. Hylek, E., et al. "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation." The New England Journal of Medicine (2003): 1019-26]
| 0 | 1 |
| --- | --- |
معرفات كيميائية:  (مُركَّب) قاعدة بيانات الكيمياء العامة (PubChem CID): 9912771  مختبَر كيمياء علم الأحياء الجزيئي الأوروبي (ChEMBL): CHEMBL1922235  المعرِّف الكيميائي الدَّولي (InChI): InChI=1S/C27H30N4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34)  مفتاح المُعرِّف الكيميائي الدولي (InChIKey): IJNIQYINMSGIPS-UHFFFAOYSA-N  دستوكس (DSSTox): DTXSID101030146  قاعدة بيانات أيض الإنسان (HMDB): HMDB0250868  معهد المعلوماتية الحيوية الأوروبي (SureChEMBL): SCHEMBL2227024  العنكبوت الكيميائي (ChemSpider): 8088422  بنود الإدخال الخطية النصية الجزيئية المبسطة القانونية (SMILES): CN1CCCN(CC1)C2=CC=C(C=C2)C(=O)NC3=C(C=CC=C3O)NC(=O)C4=CC=C(C=C4)OC  دائرة المستخلَصات الكيميائية (CAS): 365462-23-3  مستودع العقاقير (DrugBank): DB12289  المُكوِّن الفريد (UNII): KF322K101S  
| 0 | 1 |
| --- | --- |
التصنيفات الطبية:  نظام فهرسة المواضيع الطبية (MeSH): C569750  
المعرفات الخارجية:  مُختبَر كيمياء علم الأحياء الجزيئي الأوروبي (ChEMBL): CHEMBL1922235  
بوابة صيدلة
بوابة الكيمياء
بوابة طب